FDA Approves Interchangeable Lantus Biosimilar for Diabetes
PHILADELPHIA, PA — Lannett Company announced that the U.S. Food and Drug Administration approved LANGLARA, an interchangeable biosimilar to Lantus insulin, expanding the number of lower-cost insulin treatment options available …
FDA Approves Interchangeable Lantus Biosimilar for Diabetes Read More